David Gee - Cellebrite Chief Officer
| CLBTWDelisted Stock | USD 5.15 0.44 7.87% |
Executive
David Gee is Chief Officer of Cellebrite DI Equity
| Age | 57 |
| Phone | 972 73 394 8000 |
| Web | https://www.cellebrite.com |
Cellebrite Management Efficiency
The company has return on total asset (ROA) of 0.0639 % which means that it generated a profit of $0.0639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (17.6851) %, meaning that it generated substantial loss on money invested by shareholders. Cellebrite's management efficiency ratios could be used to measure how well Cellebrite manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Naemura | Neogen | 54 | |
| Tanya Zharov | Alvotech | 57 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| James Mulligan | SunLink Health Systems | 102 | |
| Theresa Mota | SunLink Health Systems | N/A | |
| Michael Karicher | Sonida Senior Living | 54 | |
| Bill Waelke | Neogen | N/A | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| Sandra Casaca | Alvotech | N/A | |
| Eva Gunnlaugsdottir | Alvotech | N/A | |
| Tat Yu | Yuexiu Transport Infrastructure | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| Christina Siniscalchi | Alvotech | N/A | |
| Amy Rocklin | Neogen | 52 | |
| Jenny Steingrimsdottir | Alvotech | N/A | |
| Sarah Demey | Neogen | N/A | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Giedrius Zunda | Alvotech | N/A | |
Management Performance
| Return On Equity | -17.69 | |||
| Return On Asset | 0.0639 |
Cellebrite DI Equity Leadership Team
Elected by the shareholders, the Cellebrite's board of directors comprises two types of representatives: Cellebrite inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellebrite. The board's role is to monitor Cellebrite's management team and ensure that shareholders' interests are well served. Cellebrite's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellebrite's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yossi Carmil, CEO Director | ||
| Thomas Hogan, Executive Chairman | ||
| Zohar TadmorEilat, Chief Officer | ||
| Osnat Tirosh, Chief Officer | ||
| Ori Nurick, Ex Management | ||
| David Gee, Chief Officer | ||
| Adam Jaffe, VP Communications | ||
| Ayala Shapira, General Counsel | ||
| Anat Paran, Executive Services | ||
| Marque Teegardin, President Management | ||
| Ronnen Armon, Chief Officer | ||
| Arnon Zilberman, Executive Operations | ||
| Andrew Kramer, Vice Relations | ||
| Dana Gerner, Chief Officer | ||
| Paul Battaglia, Sr America | ||
| Alon Klomek, Chief Officer | ||
| Lisa Cole, Chief Officer | ||
| Leeor BenPeretz, Chief Officer | ||
| Mark Gambill, Chief Officer | ||
| Marcus Jewell, Global Officer |
Cellebrite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellebrite a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.69 | |||
| Return On Asset | 0.0639 | |||
| Profit Margin | (0.29) % | |||
| Operating Margin | 0.13 % | |||
| Number Of Shares Shorted | 356.81 K | |||
| Price To Earning | 12.50 X | |||
| Revenue | 325.11 M | |||
| Gross Profit | 219.91 M | |||
| EBITDA | 43.29 M | |||
| Net Income | (81.1 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Cellebrite Stock
If you are still planning to invest in Cellebrite DI Equity check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cellebrite's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |